Although there was no statistically significant difference in the levels of anti-melanin IgA autoantibodies in melanoma patients compared with controls, 15 out from 22 melanoma patients with enhanced levels of IgA anti-melanin autoantibodies had metastatic disease (Table 1 and Figure 2). The gene discussed is CD79A; the disease is metastatic neoplasm.